Show simple item record

Conversion of Ouabain-Induced Ventricular Tachycardia in Dogs with Epicardial Lidocaine: Pharmacodynamics and Functional Effects

dc.contributor.authorScott, William A.en_US
dc.contributor.authorLevy, Robert J.en_US
dc.contributor.authorSintov, Amnonen_US
dc.contributor.authorGallagher, Kim P.en_US
dc.date.accessioned2006-09-08T19:22:04Z
dc.date.available2006-09-08T19:22:04Z
dc.date.issued1990-01en_US
dc.identifier.citationSintov, Amnon; Scott, William A.; Gallagher, Kim P.; Levy, Robert J.; (1990). "Conversion of Ouabain-Induced Ventricular Tachycardia in Dogs with Epicardial Lidocaine: Pharmacodynamics and Functional Effects." Pharmaceutical Research 7(1): 28-33. <http://hdl.handle.net/2027.42/41538>en_US
dc.identifier.issn0724-8741en_US
dc.identifier.issn1573-904Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/41538
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2300532&dopt=citationen_US
dc.description.abstractEpicardial antiarrhythmic drug administration was studied as a therapeutic approach for experimental ventricular tachycardia (VT) in an open-chest dog model. Lidocaine-polyurethane matrices (28%, w/w) were formulated as a model system. Matrices were placed on the left ventricular epicardium in each of 23 anesthetized open-chest dogs with ouabain-induced VT, to evaluate effectiveness in restoring sinus rhythm. Conversion occurred in all animals treated with matrices containing 300 mg or more of lidocaine after 1.5 to 7.0 min. The matrix lidocaine content correlated linearly with the time required for conversion to sinus rhythm ( r = 0.75, P = 0.0002); irrespective of matrix size the myocardial/plasma lidocaine ratio was 20.1 ± 4.2 (mean ± SD) at the time of conversion. In a separate series of five dogs without ventricular tachycardia, systolic wall thickening measured with sonomicrometers after 5 min of controlled-release lidocaine administration (500- to 1000-mg matrix lidocaine content, 7.48 ± 3.49-mg/kg dose) was only minimally diminished (−14.1%) and this effect was observed only at the site of matrix placement on the anterior-apical epicardium. In contrast, intracoronary injection of 0.3 or 1.0 mg/kg of lidocaine-HCl resulted in complete elimination of wall thickening or replacement by systolic thinning. Thus epicardial administration of lidocaine from polyurethane matrices was an effective means of treating ouabain-induced ventricular tachycardia. Regional myocardial function in the vicinity of the matrices was modified to a very limited degree, supporting the view that the matrices can be used safely, without serious risk to ventricular contractile performance.en_US
dc.format.extent1106442 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherControlled Releaseen_US
dc.subject.otherPharmacyen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherLidocaineen_US
dc.subject.otherMedical Lawen_US
dc.subject.otherArrhythmiaen_US
dc.subject.otherVentricular Tachycardiaen_US
dc.titleConversion of Ouabain-Induced Ventricular Tachycardia in Dogs with Epicardial Lidocaine: Pharmacodynamics and Functional Effectsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics, C. S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumDepartment of Pediatrics, C. S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumDepartment of Pediatrics, C. S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109; Kresge II, Room 5080, The University of Michigan, Box 0576, Ann Arbor, Michigan, 48109-0576en_US
dc.contributor.affiliationumDepartments of Physiology and Surgery, University of Michigan Medical School, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2300532en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/41538/1/11095_2004_Article_305656.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1015875223446en_US
dc.identifier.sourcePharmaceutical Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.